The New T Cell Subset Opens a New Realm for Tumor Immunotherapy

Immunotherapy with immune checkpoint inhibitors had achieved great success. However, only a subset of patients responds positively to these therapies. The latest study published on Nature by Chou and colleagues found a new T cell subset from tumor-infiltrating T cells which lack PD-1 on the cell sur...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Huanjin, Zeng, Chong, Wang, Weidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666835/
https://www.ncbi.nlm.nih.gov/pubmed/36377088
http://dx.doi.org/10.1177/09636897221138037
_version_ 1784831589152194560
author Zhu, Huanjin
Zeng, Chong
Wang, Weidong
author_facet Zhu, Huanjin
Zeng, Chong
Wang, Weidong
author_sort Zhu, Huanjin
collection PubMed
description Immunotherapy with immune checkpoint inhibitors had achieved great success. However, only a subset of patients responds positively to these therapies. The latest study published on Nature by Chou and colleagues found a new T cell subset from tumor-infiltrating T cells which lack PD-1 on the cell surface and potent cytotoxic activities against tumor cells. This finding provides a novel insight into the development of new therapies for tumors that do not respond to immune checkpoint blockade in the future.
format Online
Article
Text
id pubmed-9666835
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-96668352022-11-17 The New T Cell Subset Opens a New Realm for Tumor Immunotherapy Zhu, Huanjin Zeng, Chong Wang, Weidong Cell Transplant Editorial Immunotherapy with immune checkpoint inhibitors had achieved great success. However, only a subset of patients responds positively to these therapies. The latest study published on Nature by Chou and colleagues found a new T cell subset from tumor-infiltrating T cells which lack PD-1 on the cell surface and potent cytotoxic activities against tumor cells. This finding provides a novel insight into the development of new therapies for tumors that do not respond to immune checkpoint blockade in the future. SAGE Publications 2022-11-14 /pmc/articles/PMC9666835/ /pubmed/36377088 http://dx.doi.org/10.1177/09636897221138037 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Editorial
Zhu, Huanjin
Zeng, Chong
Wang, Weidong
The New T Cell Subset Opens a New Realm for Tumor Immunotherapy
title The New T Cell Subset Opens a New Realm for Tumor Immunotherapy
title_full The New T Cell Subset Opens a New Realm for Tumor Immunotherapy
title_fullStr The New T Cell Subset Opens a New Realm for Tumor Immunotherapy
title_full_unstemmed The New T Cell Subset Opens a New Realm for Tumor Immunotherapy
title_short The New T Cell Subset Opens a New Realm for Tumor Immunotherapy
title_sort new t cell subset opens a new realm for tumor immunotherapy
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666835/
https://www.ncbi.nlm.nih.gov/pubmed/36377088
http://dx.doi.org/10.1177/09636897221138037
work_keys_str_mv AT zhuhuanjin thenewtcellsubsetopensanewrealmfortumorimmunotherapy
AT zengchong thenewtcellsubsetopensanewrealmfortumorimmunotherapy
AT wangweidong thenewtcellsubsetopensanewrealmfortumorimmunotherapy
AT zhuhuanjin newtcellsubsetopensanewrealmfortumorimmunotherapy
AT zengchong newtcellsubsetopensanewrealmfortumorimmunotherapy
AT wangweidong newtcellsubsetopensanewrealmfortumorimmunotherapy

Ejemplares similares